in this issue
People & Business :: Companies
DSM Biologics and Crucell Enter Licensing Deal
2:08 PM MDT | August 20, 2007 | Michelle Bryner
DSM Biologics and Crucell (Leiden, the Netherlands) have entered into an agreement to license a new manufacturing technology based on the companies’ jointly developed PER.C6 cell line, to LFB Biotechnologies (Paris). Financial details were not disclosed. LFB will use the licensed technology to develop undisclosed antibodies. The companies will also evaluate the potential for a joint collaboration to develop sugar structures on recombinant antibodies using LFB’s proprietary technology. PER.C6 is a human cell line for producing therapeutic recombinant...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee